Next Article in Journal
Quantitative Proteomics Identifies DNA Repair as a Novel Biological Function for Hepatocyte Nuclear Factor 4α in Colorectal Cancer Cells
Next Article in Special Issue
Purinergic Calcium Signals in Tumor-Derived Endothelium
Previous Article in Journal
Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
Previous Article in Special Issue
Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) Induces Intracellular Ca2+ Release through the Two-Pore Channel TPC1 in Metastatic Colorectal Cancer Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 11
Issue 5
10.3390/cancers11050625
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

TMEM16F/Anoctamin 6 in Ferroptotic Cell Death

by
Jiraporn Ousingsawat
,
Rainer Schreiber
and
Karl Kunzelmann
*
Institut für Physiologie, Universität Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(5), 625; https://doi.org/10.3390/cancers11050625
Submission received: 10 April 2019 / Revised: 1 May 2019 / Accepted: 3 May 2019 / Published: 5 May 2019
(This article belongs to the Special Issue Ion Channels in Cancer)
Browse Figures
Versions Notes

Abstract

:
Ca2+ activated Cl− channels (TMEM16A; ANO1) support cell proliferation and cancer growth. Expression of TMEM16A is strongly enhanced in different types of malignomas. In contrast, TMEM16F (ANO6) operates as a Ca2+ activated chloride/nonselective ion channel and scrambles membrane phospholipids to expose phosphatidylserine at the cell surface. Both phospholipid scrambling and cell swelling induced through activation of nonselective ion currents appear to destabilize the plasma membrane thereby causing cell death. There is growing evidence that activation of TMEM16F contributes to various forms of regulated cell death. In the present study, we demonstrate that ferroptotic cell death, occurring during peroxidation of plasma membrane phospholipids activates TMEM16F. Ferroptosis was induced by erastin, an inhibitor of the cystine-glutamate antiporter and RSL3, an inhibitor of glutathione peroxidase 4 (GPX4). Cell death was largely reduced in the intestinal epithelium, and in peritoneal macrophages isolated from mice with tissue-specific knockout of TMEM16F. We show that TMEM16F is activated during erastin and RSL3-induced ferroptosis. In contrast, inhibition of ferroptosis by ferrostatin-1 and by inhibitors of TMEM16F block TMEM16F currents and inhibit cell death. We conclude that activation of TMEM16F is a crucial component during ferroptotic cell death, a finding that may be useful to induce cell death in cancer cells.

1. Introduction

TMEM16A-K (anoctamin 1–10) form a family of 10 paralogous proteins that are Ca2+ activated phospholipid scramblases and ion channels [1,2,3]. These proteins are broadly expressed and fulfill numerous functions in epithelial cells and other non-excitable tissues, as well neurons, smooth muscles and sensory cells. The Ca2+ activated Cl− channel TMEM16A has been analyzed in great detail, and has been found along with other members of the TMEM16 family to control cell proliferation and growth of different types of cancer (reviewed in [4,5]. Thus, inhibition of TMEM16A is a novel way to interfere with cell proliferation and growth of cancer [5,6,7,8,9].
In contrast, TMEM16F functions as Ca2+-activated phospholipid scramblase [10,11,12], while others highlighted the Ca2+ permeability of TMEM16F [13]. Most reports confirmed a Cl− permeability for TMEM16F [14,15,16,17], while others reported non-selectivity for TMEM16F [18]. We found that the TMEM16F produces Cl− selective currents at intracellular Ca2+ concentrations in the low µmolar range, while ongoing stimulation and higher intracellular Ca2+ concentrations increase non-selectivity of the channel [19]. Moreover, TMEM16F has a role in macrophage and lymphocyte death, caused by massive P2X7-induced increase in intracellular Ca2+ [15,19]. TMEM16F is also present in pre-apoptotic cells of the intestinal surface epithelium, but not in proliferative intestinal crypt cells [15]. Subsequent studies suggested a contribution of TMEM16F to different forms of regulated cell death. Pyroptosis, for example, is a highly inflammatory form of programmed cell death caused by intracellular pathogens and activation of inflammasomes [20,21]. Gasdermin D generates large plasma membrane pores, a process that depends on expression of TMEM16F [22]. Remarkably, lipid peroxidation activates TMEM16F [23] and drives pyroptosis [24]. Pore formation and cell death due to pulsed electric fields also requires activation of TMEM16F [25]. Another report demonstrated activation of TMEM16F during necroptotic cell death, although it does not seem to be essential for necroptosis [26]. TMEM16F is normally present in the so-called primary cilium of renal collecting duct epithelial cells. It is, however, highly upregulated in pre-apoptotic epithelial cells in the center of growing renal cysts, where it supports cyst expansion in polycystic kidney disease [27].
Recent data indicate that TMEM16F is also activated by an increase in reactive oxygen species (ROS) and lipid peroxidation [28], as well as phospholipid hydrolysis caused by phospholipase A2 [23]. We therefore examined in the present study the role of TMEM16F during ferroptosis, a form of regulated cell death that occurs due to accumulation of lethal phospholipid peroxides [29]. The present data obtained from mice lacking expression of TMEM16F and from TMEM16F-knockout cells in vitro, strongly suggest that elimination of TMEM16F-expression or inhibition TMEM16F protects from ferroptotic cell death. Activation of TMEM16F may therefore enhance ferroptotic cell death in cancer cells.

2. Results

2.1. Attenuated Cell Death in Epithelial Cells from Mice Lacking Expression of TMEM16F

We reported earlier a pro-apoptotic effect of TMEM16F in macrophages [19]. TMEM16F is expressed in the intestinal surface epithelium, but not in intestinal crypts [15]. Stem cells in the crypt base proliferate, while aged enterocytes in the surface epithelium are prone to cell death. These dying cells are replaced by cells from the lower crypt, which move upwards and towards the surface epithelium [30]. We generated mice with an intestinal epithelial specific knockout of TMEM16F [31]. TUNEL assays performed in intestinal epithelium of TMEM16F knockout mice unmasked an impressive inhibition of spontaneous cell death, when compared to wild type mice (Figure 1A–D). In contrast to intestinal cells, airway epithelial cells are replaced at a much lower rate. Although we did not examine airways systematically, airway epithelial-specific knockout of TMEM16F [31] also seemed to reduce cell death in the airway epithelium (Figure 1E). We isolated intestinal crypts, which typically move into anoikis, another form of programmed cell death caused by a loss of contact with the basolateral matrix [32] (Figure 1F). Ferrostatin-1, an inhibitor of ferroptosis that was also shown to inhibit activation of TMEM16A/F [33], did not suppress anoikis but inhibited ferroptotic cell death induced by RSL3 and erastin (Era) [34] (Figure 1F,G).

2.2. Reduced Ferroptosis in Macrophages from Mice Lacking Expression of TMEM16F

To further examine a potential role of TMEM16F for ferroptosis, we used Cx3cr1-Cre mice to generate a knockout of TMEM16F in macrophages (c.f. Methods) (Figure 2A,B). Macrophages express TMEM16F at relatively high levels, which has a significant impact on essential macrophage functions, as shown earlier in conventional TMEM16F knockout macrophages [19]. We induced ferroptotic cell death by RSL3 and erastin in isolated peritoneal macrophages. Cell death was detected by propidium iodide (PI) staining. Knockout of TMEM16F largely reduced ferroptosis in macrophages (Figure 2C,D). Moreover, ferrostatin-1 and different inhibitors of TMEM16F, such as niclosamide, benzbromarone, or CaCCinhAO1 strongly inhibited ferroptosis (Figire 2D). In patch clamp experiments, a whole cell current was activated by RSL3/erastin in WT macrophages, which was absent in KO macrophages (Figure 2E,F). Measurement of intracellular Ca2+ concentrations indicated a sharp increase in basal intracellular Ca2+ levels during ferroptosis, which explains the spontaneous activity of TMEM16F currents in WT macrophages (Figure 2G,H). Moreover, release of Ca2+ from intracellular endoplasmic reticulum Ca2+ stores was augmented after RSL3/erastin (Figure 2G,H).
Similar to macrophages, Jurkat T-lymphocytes also express TMEM16F, which can be activated by increase in intracellular Ca2+ using the Ca2+ ionophore ionomycin (Iono) or by lipid-peroxidizing tert-butyl hydroperoxide (tBHP) [15,23] (Figure 3A–C). Activation of TMEM16F currents was inhibited by siRNA-knockdown of TMEM16F-expression (siTMEM16F). Moreover, the pronounced ferroptotic cell death induced by RSL3/erastin was remarkably blocked by ferrostatin-1 and by the inhibitor of TMEM16F, tannic acid [35] (TA; Figure 3D,E). These results demonstrate a significant contribution of endogenous TMEM16F to ferroptosis.

2.3. Effect of Overexpressed TMEM16F and Cooperativity with TMEM16A

Overexpressed TMEM16F scrambles plasma membrane phospholipids and conducts ions [36]. We overexpressed TMEM16F in HEK293 cells and analyzed exposure of phosphatidylserine (PS; annexing V binding) by flow cytometry, upon stimulation with ionomycin (Figure 4A,B). We detected low but detectable scrambling activity also in mock transfected cells, which was due to endogenous expression of TMEM16F, as demonstrated by siRNA-knockout of TMEM16F. Interestingly, TMEM16A also augmented PS exposure, which was however, abolished by simultaneous knockdown of TMEM16F. Because TMEM16A does not scramble phospholipids, but augments Ca2+ store release and consecutive store operated Ca2+ entry (SOCE) [37,38], we suggest that TMEM16A induces PS exposure indirectly by activation of SOCE that provides Ca2+ for activation of TMEM16F [38].

2.4. Ferroptosis Induced in Cancer Cells

TMEM16F is widely expressed in different cell types, including macrophages and lymphocytes, pre-apoptotic cells, and cancer cells [26,39]. By measuring LDH release, we found that ferroptotic cell death is induced in human A549 pulmonary adenocarcinoma, Cal27 head and neck cancer, HT29 colonic carcinoma, and MG-63 osteosarcoma cells, respectively. LDH release was completely inhibited by ferrostatin-1 (Figure 5A). Destabilization of the plasma membrane is an essential feature of lipid peroxidation/ferroptotic cell death, which also occurs during activation of phospholipase A2 (PLA2) [29,35]. Both lipid peroxidation and PLA2 activates TMEM16F [23]. We found that similar to RSL3/erastin, the PLA2-activator melittin induced release of LDH (Figure 5B) and uptake of 7-AAD (a replacement for propidium iodide), as detected by flow cytometry (Figure 6). Overexpression of TMEM16 proteins in HEK293 cells confirms that activation of TMEM16F, but not TMEM16A, is responsible for melittin-induced cell death. Thus, TMEM16F is an essential factor that contributes to membrane destabilization during induction of ferroptotic cell death, probably due to its ability to scramble membrane phospholipids. Direct activation of TMEM16F may therefore resemble a novel strategy for induction of cell death in cancer cells.

3. Discussion

TMEM16F is broadly expressed in all types of tissues, albeit at very different levels. It appears to be upregulated in cells undergoing regulated cell death [15,27]. Here, we provide evidence that TMEM16F is activated during ferroptosis, a regulated cell death pathway triggered by oxidation of preferentially polyunsaturated fatty acid (PUFA)-containing membrane phospholipids [29]. Ferroptosis is induced experimentally using erastin, an inhibitor of the cystine-glutamate antiporter System Xc-(SLC7A11). Cystine import into cells is required to produce glutathione (GSH) used by glutathione peroxidase 4 (GPX4) to eliminate lipid peroxides. RSL3, an inhibitor of GPX4, further augments ferroptosis. Ferroptotic cell death may trigger sterile inflammation through the release of danger-associated molecular patterns (DAMP), recognized by innate immune receptors. Thus, ferroptotic cell death and TLR4-dependent signaling in graft endothelial cells is causing tissue inflammation after cardiac transplantation [40]. Similarly, acute kidney injury and synchronized renal tubular cell death involves ferroptosis [41].
We showed earlier that ROS induced lipid peroxidation activates TMEM16F (and TMEM16A) in a Ca2+ independent fashion. Moreover, plasma membrane lipid modifications through other pathways such as phospholipase A2 (PLA2) also activate both TMEM16A and TMEM16F [23]. The lipid-dependence of TMEM16 proteins may not be surprising given the intimacy between the TMEM16 pore and membrane phospholipids [12,42,43,44]. The structure of TMEM16F is highly dynamic, with an equilibrium between different states. This suggests additional factors apart from calcium, which may tightly lock the pore in either a closed state, an intermediate state allowing transport of ions, or a phospholipid transporting state [42,45]. Recent structural analysis of TMEM16F may also provide an explanation for the differences between overexpressed and endogenous TMEM16, and their temperature-dependence [23,46,47].
TMEM16F scrambles phospholipids and conducts cations and anions. We found earlier that ongoing stimulation by the Ca2+ ionophore ionomycin induces non-selectivity of the ion current produced by TMEM16F [19]. A nonselective TMEM16F current will depolarize the membrane voltage and lead to cell swelling. Cell swelling in conjunction with phospholipid scrambling, membrane blebbing and destabilization of the plasma membrane, explains cell death elicited by activation of TMEM16F [19,25,48,49]. Interestingly, lipid peroxidation drives gasdermin D-mediated pyroptosis in lethal polymicrobial sepsis [24]. This may explain why we also found a role of TMEM16F in pyroptosis [22].
Induction of ferroptotic cell death is considered a novel pathway to eliminate cancer cells [50,51]. This is achieved by using agents that increase ROS generation, or by compounds that inhibit antioxidant defense [28]. Some of these compounds have already entered clinical trials. They can kill cancer cells effectively and can antagonize the development of drug resistance. Because the present data demonstrate a central role of TMEM16F during ferroptotic cell death, we propose direct activation of TMEM16F as a promising new strategy to interfere with cancer growth.
TMEM16F supports Ca2+ activated membrane trafficking and controls membrane exocytosis [52,53]. Possible underlying mechanisms have been discussed recently [54]. Along this line, membrane exposure of LRRC8A, the essential subunit of the volume regulated anion channel (VRAC), depends on activation of TMEM16A [55]. VRAC controls cell death and chemoresistance of cancer cells, and is therefore of relevance for tumor biology [56,57]. As shown in Figure 4, activation of TMEM16A supports phospholipid scrambling by activating TMEM16F and therefore supports activation of VRAC [58]. Thus, it is not surprising that the potent inhibitor of TMEM16A, niclosamide, also inhibits activation of VRAC [59] (Figure 7). Taken together, while TMEM16A supports growth of cancer, activation of TMEM16F instead promotes cell death [60]. As there are currently no specific activators or inhibitors available for the different TMEM16 paralogues, it will be necessary to search for novel small molecule compounds that specifically activate TMEM16F, to be used in the future treatment of cancer.

4. Methods

4.1. Immunocytochemistry

Cells were fixed for 10 min with 4% (w/v) paraformaldehyde at room temperature. After washing, cells were permeabilized with 0.5% (v/v, PBS) Triton X-100 for 10 min and blocked with 1% (w/v, PBS) bovine serum albumin for 1 h at room temperature. Cells were incubated for 1 h with primary antibodies (1:300) against TMEM16F (Davids Biotechnology, Regensburg, Germany). Binding of the primary antibody was visualized by incubation with appropriate secondary antibodies conjugated with AlexaFluor 488 (1:500, Molecular Probes, Invitrogen). Nuclei were stained with Hoe33342 (0.1 g/mL PBS, Applichem, Darmstadt, Germany) or DAPI. Glass cover slips were mounted on glass slides with fluorescent mounting medium (DAKO Cytomation, Hamburg, Germany) and examined with an ApoTome Axiovert 200 M fluorescence microscope (Zeiss, Germany).

4.2. Isolation of Total RNA and RT-PCR

For semi-quantitative RT-PCR of TMEM16F and TMEM16A, mRNA expression in proximal and distal segments of the mouse colonic epithelium, total RNA was isolated using NucleoSpin RNA II columns (Macherey-Nagel, Düren, Germany). Total RNA (1 µg/50 µL reaction) was reverse-transcribed using random primer (Promega, Mannheim, Germany) and M-MLV reverse transcriptase RNase H Minus (Promega, Mannheim, Germany). Each RT-PCR reaction contained sense and antisense primer for mouse TMEM16A and TMEM16F [39], 0.5 µL cDNA and GoTaq Polymerase (Promega, Mannheim, Germany). After 2 min at 95 °C cDNA was amplified 25 cycles for 30 s at 95 °C, 30 s at 56 °C and 1 min at 72 °C. PCR products were visualized by loading on Midori Green Xtra (NIPPON Genetics, Dueren, Germany) containing agarose gels and analyzed using ImageJ (NIH, Bethesda, MA, USA).

4.3. Calcium Measurements

Cells were seeded on glass cover slips and loaded with 2 µM Fura-2/AM and 0.02% Pluronic F-127 (Invitrogen, Darmstadt, Germany) in ringer solution (mmol/L: NaCl 145; KH2PO4 0,4; K2HPO4 1,6; Glucose 5; MgCl2 1; Ca2+-Gluconat 1,3) for 1 h at room temperature. Fluorescence was detected in cells perfused with Ringer’s solution at 37 °C using an inverted microscope (Axiovert S100, Zeiss, Germany) and a high speed polychromator system (VisiChrome, Puchheim, Germany). Fura-2 was excited at 340/380 nm, and emission was recorded between 470 nm and 550 nm using a CoolSnap camera (CoolSnap HQ, Visitron, Puchheim, Germany). [Ca2+]i was calculated from the 340/380 nm fluorescence ratio after background subtraction. The formula used to calculate [Ca2+]i was [Ca2+]i = Kd × (R − Rmin)/(Rmax − R) × (Sf2/Sb2), where R is the observed fluorescence ratio. The values Rmax and Rmin (maximum and minimum ratios) and the constant Sf2/Sb2 (fluorescence of free and Ca2+-bound Fura-2 at 380 nm) were calculated using 1 µM ionomycin (Calbiochem), 5 µM nigericin, 10 µM monensin (Sigma, Taufkirchen, Germany), and 5 mM EGTA to equilibrate intracellular and extracellular Ca2+ in intact Fura-2-loaded cells. The dissociation constant for the Fura-2•Ca2+ complex was taken as 224 nmol/L. Control of experiments, imaging acquisition, and data analysis were done with the software package Meta-Fluor (Molecular Devices, Biberach, Germany) and Origin (OriginLab Corporation, Northampton, MA, USA).

4.4. Patch Clamping

Cells were seeded on fibronectin-coated glass-coated cover slips and were mounted on the stage of an inverted microscope (Axiovert, Zeiss, Munich, Germany). Patch pipettes were filled with a cytosolic-like solution containing 30 mM KCl, 95 mM K-gluconate, 1.2 mM NaH2PO4, 4.8 mM Na2HPO4, 1 mM EGTA, 0.758 mM Ca-gluconate, 1.03 mM MgCl2, 5 mM D-glucose, and 3 mM ATP, pH 7.2. The intracellular (pipette) Ca2+ activity was 0.1 mM. Experiments were performed in the fast whole-cell current recordings mode. The bath was perfused continuously with Ringer solution at a rate of 8 mL/min. Patch pipettes had an input resistance of 2–4 MΩ, and whole-cell currents were corrected for serial resistance. Currents were recorded using patch clamp amplifiers (EPC 7 or EPC10; List Medical Electronics, Darmstadt, Germany), the LIH1600 interface, and PULSE software (HEKA, Lambrecht, Germany) as well as Chart software (AD Instruments, Spechbach, Germany). Cell were kept most of the time under current clamp. In regular intervals, membrane voltage (Vc) was clamped in steps of 20 mV from −100 to +100 mV from a holding voltage of −100 mV. Current densities were calculated by dividing whole-cell currents by cell capacitance.

4.5. TUNEL Assay

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) in intestine from mice with intestinal epithelial specific knockout of TMEM16F (TMEM16Ffl/fl-Vil1-Cre) and WT littermate controls (TMEM16Ffl/fl) was performed in PFA fixed tissue, embedded in paraffin. For TUNEL assay, the DeadEnd Fluorometrie TUNEL system (Promega, Mannheim, Germany) was used according to manufacturer’s instructions.

4.6. Flow Cytometry

Cells were collected using accutase (Capricorn Scientific, Ebsdorfergrund, Germany), washed with cold Dulbecco’s PBS (DPBS) and centrifuged at 500 g and 4 °C for 10 min. Subsequently, cells were resuspended in 100 μL annexin binding buffer containing 5 μL annexin V-FITC and 2.5 μL 7-aminoactinomycin D (7-AAD; BioLegend, Koblenz, Germany). Cells were incubated with 1 μM ionomycin for 10 min or erastin (5 µM)/RSL3 (0.1 µM) (6 h), or melittin (0.5 µM; 14 h), respectively. Reactions were stopped by adding 400 μL DPBS and cells were analysed immediately. Fluorescence activated cell sorting (FACS) analyses was performed in Annexin V standard binding buffer (BioLegend, San Diego, CA, USA) containing 10 mM Hepes, 140 mM NaCl and 2.5 mM CaCl. For each measurement, at least 10,000 cells were analysed by flow cytometry at 37 °C (BD AccuriTM C6, St. Ives, UK) 7-AAD, a non-permeant dye, was used to identify cells with plasma membrane leakage. Freshly isolated macrophages were stained with propidium iodide staining to detect RSL3/erastin-induced cell death.

4.7. LDH Assay

Supernatants from 8 × 104 treated cells were collected from non-treated cells, cells treated with erastin/RSL3 (5 µM)/0.1 µM; 6 h) or erastin/RSL3 + ferrostain-1 (5 µM) (all 6 h) and were measured using the CytoTox96® non-radioactive cytotoxicity assay (Promega) at a wavelength of 490 nm. Percentage of LDH release was calculated as 100 × (experimental LDH-spontaneous LDH)/(maximum LDH release-spontaneous LDH).

4.8. Knockout Animals

TMEM16F was knocked-out in macrophages by crossbreeding with Cx3cr1-Cre mice (TMEM16Ffl/fl-Cx3cr1-Cre). Knockout of TMEM16F expression in intestinal epithelial cells was achieved by crossbreeding with Vil1-Cre mice (TMEM16Ffl/fl-Vil1-Cre; KO) [31]. WT littermates (TMEM16Ffl/fl; WT) served as controls.

4.9. Material and Statistical Analysis

Student’s t test for paired samples and ANOVA were used for statistical analysis. p < 0.05 was accepted as significant difference. HT29, MG63, A549, and Cal273 cells were from ATCC. All animal experiments were approved by the local Ethics Committee of the Government of Unterfranken/Würzburg (AZ: 55.2-2532-2-328) and were conducted according to the guidelines of the American Physiologic Society and German Law for the Welfare of Animals.

5. Conclusions

TMEM16A is overexpressed in a subset of malignomas where it drives cellular dedifferentiation, cell proliferation and thus supports growth of cancer cells [5]. A number of cellular signaling molecules appear to contribute to this pro-proliferative effect, however, TMEM16A-induced filling of the ER Ca2+ store and enhanced cytosolic Ca2+ signaling, appear to be major factors. While TMEM16A is overexpressed only in a subset of cancers, TMEM16F is expressed consistently at lower levels. Activation of TMEM16F supports different forms of regulated cell death. It is highly relevant for ferroptotic cell death, probably due to its plasma membrane destabilizing effect. Phospholipid scrambling and parallel activation of nonselective ion currents that leads to cell swelling, may support cell death. Thus, direct activation of TMEM16F in cancer cells is likely to kill cancer cells. The combined application with specific inhibitors of TMEM16A may reflect a novel powerful therapeutic strategy. This will require identification of paralog-specific activators and inhibitors.

Author Contributions

Conceptualization, J.O., R.S. and K.K.; methodology, J.O., R.S. and K.K.; validation, J.O., R.S. and K.K.; formal analysis, J.O., R.S. and K.K.; investigation, J.O., R.S. and K.K.; data curation, J.O., R.S. and K.K.; writing—review and editing, K.K.; visualization, J.O., R.S. and K.K.; funding acquisition, K.K. and R.S.

Funding

Supported by “Deutsche Forschungsgemeinschaft (DFG)—Projektnummer 387509280—SFB 1350“, DFG KU756/14-1, Cystic Fibrosis Trust SRC 013, Gilead Stiftung, and Mukoviszidose Institut.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Yang, Y.D.; Cho, H.; Koo, J.Y.; Tak, M.H.; Cho, Y.; Shim, W.S.; Park, S.P.; Lee, J.; Lee, B.; Kim, B.M.; et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 2008, 455, 1210–1215. [Google Scholar] [CrossRef] [PubMed]
  2. Schroeder, B.C.; Cheng, T.; Jan, Y.N.; Jan, L.Y. Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 2008, 134, 1019–1029. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Caputo, A.; Caci, E.; Ferrera, L.; Pedemonte, N.; Barsanti, C.; Sondo, E.; Pfeffer, U.; Ravazzolo, R.; Zegarra-Moran, O.; Galietta, L.J. TMEM16A, A Membrane Protein Associated with Calcium-Dependent Chloride Channel Activity. Science 2008, 322, 590–594. [Google Scholar] [CrossRef]
  4. Wang, H.; Zou, L.; Ma, K.; Yu, J.; Wu, H.; Wei, M.; Xiao, Q. Cell-specific mechanisms of TMEM16A Ca2+-activated chloride channel in cancer. Mol. Cancer 2017, 16, 152. [Google Scholar] [CrossRef]
  5. Kunzelmann, K.; Ousingsawat, J.; Benedetto, R.; Cabrita, I.; Schreiber, R. Growth and death by anoctamins. Cancers 2019, 19, E382. [Google Scholar] [CrossRef]
  6. Ruiz, C.; Martins, J.R.; Rudin, F.; Schneider, S.; Dietsche, T.; Fischer, C.A.; Tornillo, L.; Terracciano, L.M.; Schreiber, R.; Bubendorf, L.; et al. Enhanced Expression of ANO1 in Head and Neck Squamous Cell Carcinoma Causes Cell Migration and Correlates with Poor Prognosis. PLoS ONE 2012, 7, E43265. [Google Scholar] [CrossRef]
  7. Song, Y.; Gao, J.; Guan, L.; Chen, X.; Gao, J.; Wang, K. Inhibition of ANO1/TMEM16A induces apoptosis in human prostate carcinoma cells by activating TNF-alpha signaling. Cell Death Dis. 2018, 9, 703. [Google Scholar] [CrossRef]
  8. Seo, Y.; Park, J.; Kim, M.; Lee, H.K.; Kim, J.H.; Jeong, J.H.; Namkung, W. Inhibition of ANO1/TMEM16A Chloride Channel by Idebenone and Its Cytotoxicity to Cancer Cell Lines. PLoS ONE 2015, 10, E0133656. [Google Scholar] [CrossRef]
  9. Godse, N.R.; Khan, N.I.; Yochum, Z.A.; Gomez-Casal, R.; Kemp, C.; Shiwarski, D.J.; Seethala, R.; Kulich, S.; Seshadri, M.; Burns, T.F.; et al. TMEM16A/ANO1 inhibits apoptosis via down-regulation of Bim expression. Clin. Cancer Res. 2017, 23, 7324–7332. [Google Scholar] [CrossRef]
  10. Suzuki, J.; Umeda, M.; Sims, P.J.; Nagata, S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010, 468, 834–838. [Google Scholar] [CrossRef] [Green Version]
  11. Watanabe, R.; Sakuragi, T.; Noji, H.; Nagata, S. Single-molecule analysis of phospholipid scrambling by TMEM16F. Proc. Natl. Acad. Sci. USA 2018, 115, 3066–3071. [Google Scholar] [CrossRef] [Green Version]
  12. Brunner, J.D.; Lim, N.K.; Schenck, S.; Duerst, A.; Dutzler, R. X-ray structure of a calcium-activated TMEM16 lipid scramblase. Nature 2014, 516, 207–212. [Google Scholar] [CrossRef]
  13. Yang, H.; Kim, A.; David, T.; Palmer, D.; Jin, T.; Tien, J.; Huang, F.; Cheng, T.; Coughlin, S.R.; Jan, Y.N.; et al. TMEM16F Forms a Ca2+-Activated Cation Channel Required for Lipid Scrambling in Platelets during Blood Coagulation. Cell 2012, 151, 111–122. [Google Scholar] [CrossRef] [PubMed]
  14. Tian, Y.; Schreiber, R.; Kunzelmann, K. Anoctamins are a family of Ca2+ activated Cl− channels. J. Cell Sci. 2012, 125, 4991–4998. [Google Scholar] [CrossRef]
  15. Martins, J.R.; Faria, D.; Kongsuphol, P.; Reisch, B.; Schreiber, R.; Kunzelmann, K. Anoctamin 6 is an essential component of the outwardly rectifying chloride channel. Proc. Natl. Acad. Sci. USA 2011, 108, 18168–18172. [Google Scholar] [CrossRef] [Green Version]
  16. Shimizu, T.; Iehara, T.; Sato, K.; Fujii, T.; Sakai, H.; Okada, Y. TMEM16F is a component of a Ca2+-activated Cl− channel but not a volume-sensitive outwardly rectifying Cl− channel. Am. J. Physiol. Cell Physiol. 2013, 304, C748–C759. [Google Scholar] [CrossRef]
  17. Grubb, S.; Poulsen, K.A.; Juul, C.A.; Kyed, T.; Klausen, T.K.; Larsen, E.H.; Hoffmann, E.K. TMEM16F (Anoctamin 6), an anion channel of delayed Ca2+ activation. J. Gen. Physiol. 2013, 141, 585–600. [Google Scholar] [CrossRef] [PubMed]
  18. Yu, K.; Whitlock, J.M.; Lee, K.; Ortlund, E.A.; Yuan, C.Y.; Hartzell, H.C. Identification of a lipid scrambling domain in ANO6/TMEM16F. eLife 2015, 4, e06901. [Google Scholar] [CrossRef] [Green Version]
  19. Ousingsawat, J.; Wanitchakool, P.; Kmit, A.; Romao, A.M.; Jantarajit, W.; Schreiber, S.; Kunzelmann, K. Anoctamin 6 mediates effects essential for innate immunity downstream of P2X7-receptors in macrophages. Nat. Commun. 2015, 6, 6245. [Google Scholar] [CrossRef] [PubMed]
  20. Kayagaki, N.; Stowe, I.B.; Lee, B.L.; O’Rourke, K.; Anderson, K.; Warming, S.; Cuellar, T.; Haley, B.; Roose-Girma, M.; Phung, Q.T.; et al. (Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 2015, 526, 666–671. [Google Scholar]
  21. Shi, J.; Zhao, Y.; Wang, K.; Shi, X.; Wang, Y.; Huang, H.; Zhuang, Y.; Cai, T.; Wang, F.; Shao, F. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015, 526, 660–665. [Google Scholar] [CrossRef]
  22. Ousingsawat, J.; Wanitchakool, P.; Schreiber, R.; Kunzelmann, K. Contribution of TMEM16F to pyroptotic cell death. Cell Death Dis. 2018, 9, 300. [Google Scholar] [CrossRef] [PubMed]
  23. Schreiber, R.; Ousingsawat, J.; Wanitchakool, P.; Sirianant, L.; Benedetto, R.; Reiss, K.; Kunzelmann, K. Regulation of TMEM16A/ANO1 and TMEM16F/ANO6 ion currents and phospholipid scrambling by Ca2+ and plasma membrane lipid. J. Physiol. 2018, 596, 217–229. [Google Scholar] [CrossRef]
  24. Kang, R.; Zeng, L.; Zhu, S.; Xie, Y.; Liu, J.; Wen, Q.; Cao, L.; Xie, M.; Ran, Q.; Kroemer, G.; et al. Lipid Peroxidation Drives Gasdermin D-Mediated Pyroptosis in Lethal Polymicrobial Sepsis. Cell Host Microbe 2018, 24, 97–108. [Google Scholar] [CrossRef] [PubMed]
  25. Muratori, C.; Pakhomov, A.G.; Gianulis, E.; Meads, J.; Casciola, M.; Mollica, P.A.; Pakhomova, O.N. Activation of the phospholipid scramblase TMEM16F by nanosecond pulsed electric field (nsPEF) facilitates its diverse cytophysiological effects. J. Biol. Chem. 2017, 292, 19381–19391. [Google Scholar] [CrossRef] [PubMed]
  26. Ousingsawat, J.; Cabrita, I.; Wanitchakool, P.; Sirianant, L.; Krautwald, S.; Linkermann, A.; Schreiber, R.; Kunzelmann, K. Ca2+ signals, cell membrane disintegration, and activation of TMEM16F during necroptosis. Cell. Mol. Life Sci. 2016, 74, 173–181. [Google Scholar] [CrossRef]
  27. Forschbach, V.; Goppelt-Struebe, M.; Kunzelmann, K.; Schreiber, R.; Piedagnel, R.; Kraus, A.; Eckardt, K.U.; Buchholz, B. Anoctamin 6 is localized in the primary cilium of renal tubular cells and is involved in apoptosis-dependent cyst lumen formation. Cell Death Dis. 2015, 6, E1899. [Google Scholar] [CrossRef] [PubMed]
  28. Simoes, F.; Ousingsawat, J.; Wanitchakool, P.; Fonseca, A.; Cabrita, I.; Benedetto, R.; Schreiber, R.; Kunzelmann, K. CFTR supports cell death through ROS-dependent activation of TMEM16F (anoctamin 6). Pflugers Arch. 2018, 470, 305–314. [Google Scholar] [CrossRef]
  29. Stockwell, B.R.; Friedmann Angeli, J.P.; Bayir, H.; Bush, A.I.; Conrad, M.; Dixon, S.J.; Fulda, S.; Gascon, S.; Hatzios, S.K.; Kagan, V.E.; et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 2017, 171, 273–285. [Google Scholar] [CrossRef]
  30. Crosnier, C.; Stamataki, D.; Lewis, J. Organizing cell renewal in the intestine: Stem cells, signals and combinatorial control. Nat. Rev. Genet. 2006, 7, 349–359. [Google Scholar] [CrossRef] [PubMed]
  31. Cabrita, I.; Benedetto, R.; Schreiber, R.; Kunzelmann, K. Niclosamide repurposed for the treatment of inflammatory airway disease. JCI Insight 2019. under review. [Google Scholar]
  32. Strater, J.; Wedding, U.; Barth, T.F.; Koretz, K.; Elsing, C.; Moller, P. Rapid onset of apoptosis in vitro follows disruption of beta 1-integrin/matrix interactions in human colonic crypt cells. Gastroenterology 1996, 110, 1776–1784. [Google Scholar] [CrossRef]
  33. Schreiber, R.; Buchholz, B.; Kraus, A.; Schley, G.; Scholz, J.; Ousingsawat, J.; Kunzelmann, K. Lipid peroxidation drives renal cyst growth in vitro through activation of TMEM16A. J. Am. Soc. Nephrol. 2019, 30, 228–242. [Google Scholar] [CrossRef]
  34. Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.; Cantley, A.M.; Yang, W.S.; et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012, 149, 1060–1072. [Google Scholar] [CrossRef]
  35. Sirianant, L.; Ousingsawat, J.; Wanitchakool, P.; Schreiber, R.; Kunzelmann, K. Cellular Volume regulation by Anoctamin 6: Ca2+, phospholipase A2,osmosensing. Pflügers Arch. 2015, 468, 335–349. [Google Scholar]
  36. Kunzelmann, K.; Nilius, B.; Owsianik, G.; Schreiber, R.; Ousingsawat, J.; Sirianant, L.; Wanitchakool, P.; Bevers, E.M.; Heemskerk, J.W. Molecular functions of anoctamin 6 (TMEM16F): A. chloride channel, cation channel or phospholipid scramblase? Pflügers Arch. 2014, 466, 407–414. [Google Scholar] [CrossRef] [PubMed]
  37. Gyobu, S.; Ishihara, K.; Suzuki, J.; Segawa, K.; Nagata, S. Characterization of the scrambling domain of the TMEM16 family. Proc. Natl. Acad. Sci. USA 2017, 114, 6274–6279. [Google Scholar] [CrossRef]
  38. Cabrita, I.; Benedetto, R.; Fonseca, A.; Wanitchakool, P.; Sirianant, L.; Skryabin, B.V.; Schenk, L.K.; Pavenstadt, H.; Schreiber, R.; Kunzelmann, K. Differential effects of anoctamins on intracellular calcium signals. FASEB J. 2017, 31, 2123–2134. [Google Scholar] [CrossRef] [PubMed]
  39. Schreiber, R.; Uliyakina, I.; Kongsuphol, P.; Warth, R.; Mirza, M.; Martins, J.R.; Kunzelmann, K. Expression and Function of Epithelial Anoctamins. J. Biol. Chem. 2010, 285, 7838–7845. [Google Scholar] [CrossRef]
  40. Li, W.; Feng, G.; Gauthier, J.M.; Lokshina, I.; Higashikubo, R.; Evans, S.; Liu, X.; Hassan, A.; Tanaka, S.; Cicka, M.; et al. Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation. J. Clin. Investig. 2019, 130, 126428. [Google Scholar] [CrossRef]
  41. Linkermann, A.; Skouta, R.; Himmerkus, N.; Mulay, S.R.; Dewitz, C.; De Zen, F.; Prokai, A.; Zuchtriegel, G.; Krombach, F.; Welz, P.S.; et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl. Acad. Sci. USA 2014, 111, 16836–16841. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Alvadia, C.; Lim, N.K.; Clerico Mosina, V.; Oostergetel, G.T.; Dutzler, R.; Paulino, C. Cryo-EM structures and functional characterization of the murine lipid scramblase TMEM16F. eLife 2019, 8, e44365. [Google Scholar] [CrossRef]
  43. Paulino, C.; Kalienkova, V.; Lam, A.K.M.; Neldner, Y.; Dutzler, R. Activation mechanism of the calcium-activated chloride channel TMEM16A revealed by cryo-EM. Nature 2017, 552, 421–425. [Google Scholar] [CrossRef]
  44. Dang, S.; Feng, S.; Tien, J.; Peters, C.J.; Bulkley, D.; Lolicato, M.; Zhao, J.; Zuberbuhler, K.; Ye, W.; Qi, L.; et al. Cryo-EM structures of the TMEM16A calcium-activated chloride channel. Nature 2017, 552, 426. [Google Scholar] [CrossRef]
  45. Kalienkova, V.; Clerico Mosina, V.; Bryner, L.; Oostergetel, G.T.; Dutzler, R.; Paulino, C. Stepwise activation mechanism of the scramblase nhTMEM16 revealed by cryo-EM. eLife 2019, 8, e44364. [Google Scholar] [CrossRef]
  46. Tian, Y.; Schreiber, R.; Wanitchakool, P.; Kongsuphol, P.; Sousa, M.; Uliyakina, I.; Palma, M.; Faria, D.; Traynor-Kaplen, A.E.; Fragata, J.I.; et al. Control of TMEM16A by INO-4995 and other inositolphosphates. Br. J. Pharmacol. 2012, 168, 253–265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Cho, H.; Oh, U. Anoctamin 1 mediates thermal pain as a heat sensor. Curr. Neuropharmacol. 2013, 11, 641–651. [Google Scholar] [CrossRef]
  48. Mattheij, N.J.; Braun, A.; van Kruchten, R.; Castoldi, E.; Pircher, J.; Baaten, C.C.; Wulling, M.; Kuijpers, M.J.; Kohler, R.; Poole, A.W.; et al. Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling, swelling, and protein cleavage. FASEB J. 2015, 30, 727–737. [Google Scholar] [CrossRef]
  49. Liu, G.; Liu, G.; Chen, H.; Borst, O.; Gawaz, M.; Vortkamp, A.; Schreiber, R.; Kunzelmann, K.; Lang, F. Involvement of Ca2+ Activated Cl− Channel Ano6 in Platelet Activation and Apoptosis. Cell Physiol. Biochem. 2015, 37, 1934–1944. [Google Scholar] [CrossRef]
  50. Mou, Y.; Wang, J.; Wu, J.; He, D.; Zhang, C.; Duan, C.; Li, B. Ferroptosis, a new form of cell death: Opportunities and challenges in cancer. J. Hematol. Oncol. 2019, 12, 34. [Google Scholar] [CrossRef]
  51. Galadari, S.; Rahman, A.; Pallichankandy, S.; Thayyullathil, F. Reactive oxygen species and cancer paradox: To promote or to suppress? Free Rad. Biol. Med. 2017, 104, 144–164. [Google Scholar] [CrossRef]
  52. Bricogne, C.; Fine, M.; Pereira, P.M.; Sung, J.; Tijani, M.; Wang, Y.; Henriques, R.; Collins, M.K.; Hilgemann, D. TMEM16F activation by Ca2+ triggers plasma membrane expansion and directs PD-1 trafficking. Sci. Rep. 2019, 9, 619. [Google Scholar] [CrossRef] [PubMed]
  53. Benedetto, R.; Cabrita, I.; Schreiber, R.; Kunzelmann, K. TMEM16A is indispensable for basal mucus secretion in airways and intestine. FASEB J. 2019, 33, 4502–4512. [Google Scholar] [CrossRef] [PubMed]
  54. Benedetto, R.; Ousingsawat, J.; Cabrita, I.; Pinto, M.; Lerias, J.; Wanitchakool, P.; Schreiber, R.; Kunzelmann, K. Plasma membrane localized TMEM16 Proteins are Indispensable for expression of CFTR. J. Mol. Med. 2019, 97, 711–722. [Google Scholar] [CrossRef]
  55. Benedetto, R.; Sirianant, L.; Pankonien, I.; Wanitchakool, P.; Ousingsawat, J.; Cabrita, I.; Schreiber, R.; Amaral, M.; Kunzelmann, K. Relationship between TMEM16A/anoctamin 1 and LRRC8A. Pflugers Arch. 2016, 468, 1751–1763. [Google Scholar] [CrossRef]
  56. Planells-Cases, R.; Lutter, D.; Guyader, C.; Gerhards, N.M.; Ullrich, F.; Elger, D.A.; Kucukosmanoglu, A.; Xu, G.; Voss, F.K.; Reincke, S.M.; et al. Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. EMBO J. 2015, 34, 2993–3008. [Google Scholar] [CrossRef] [PubMed]
  57. Zhang, H.; Deng, Z.; Zhang, D.; Li, H.; Zhang, L.; Niu, J.; Zuo, W.; Fu, R.; Fan, L.; Ye, J.H.; et al. High expression of leucinerich repeatcontaining 8A is indicative of a worse outcome of colon cancer patients by enhancing cancer cell growth and metastasis. Oncology Rep. 2018, 40, 1275–1286. [Google Scholar] [CrossRef]
  58. Almaca, J.; Tian, Y.; AlDehni, F.; Ousingsawat, J.; Kongsuphol, P.; Rock, J.R.; Harfe, B.D.; Schreiber, R.; Kunzelmann, K. TMEM16 proteins produce volume regulated chloride currents that are reduced in mice lacking TMEM16A. J. Biol. Chem. 2009, 284, 28571–28578. [Google Scholar] [CrossRef]
  59. Miner, K.; Labitzke, K.; Liu, B.; Elliot, R.; Wang, P.; Henckels, K.; Gaida, K.; Elliot, R.; Chen, J.J.; Liu, L.; et al. The Anthelminthic Niclosamide And Related Compounds Represent Potent Tmem16a Antagonists That Fully Relax Mouse and Human Airway Rings. Frontiers Pharmacol. 2019, 14. [Google Scholar] [CrossRef]
  60. Zhao, P.; Torcaso, A.; Mariano, A.; Xu, L.; Mohsin, S.; Zhao, L.; Han, R. Anoctamin 6 Regulates C2C12 Myoblast Proliferation. PLoS ONE 2014, 9, E92749. [Google Scholar] [CrossRef]
Cancers 11 00625 g001a 550Cancers 11 00625 g001b 550
Figure 1. Attenuated cell death in epithelial cells from mice lacking expression of TMEM16F. (A) TUNEL staining in intestinal epithelium of mice with intestinal epithelial specific knockout of TMEM16F (TMEM16Ffl/fl-Vil1-Cre; KO) and WT littermate controls (TMEM16Ffl/fl; WT). Bar = 100 µm. (B) RT-PCR indicating lack of expression of TMEM16F in isolated crypts of TMEM16F knockout animals. (C,D) Summary of the number of TUNEL-positive crypts per section and the number of TUNEL-positive cells per individual crypt, respectively. (E) TUNEL positive cells in airways of WT mice and mice with airway epithelial specific knockout of TMEM16F [31]. Bar = 50 µm. (F,G) Propidium iodide staining in isolated mouse crypts and activation of ferroptosis by RSL3 (1 µM) and erastin (5 µM) (RSL3+Era). Inhibition of ferroptotic cell death by ferrostatin-1 (Fer-1; 5 µM). Bar = 100 µm. Mean ± SEM (number of experiments). # significant difference compared to WT, con, or RSL3+Era, respectively (p < 0.05, unpaired t-test).
Figure 1. Attenuated cell death in epithelial cells from mice lacking expression of TMEM16F. (A) TUNEL staining in intestinal epithelium of mice with intestinal epithelial specific knockout of TMEM16F (TMEM16Ffl/fl-Vil1-Cre; KO) and WT littermate controls (TMEM16Ffl/fl; WT). Bar = 100 µm. (B) RT-PCR indicating lack of expression of TMEM16F in isolated crypts of TMEM16F knockout animals. (C,D) Summary of the number of TUNEL-positive crypts per section and the number of TUNEL-positive cells per individual crypt, respectively. (E) TUNEL positive cells in airways of WT mice and mice with airway epithelial specific knockout of TMEM16F [31]. Bar = 50 µm. (F,G) Propidium iodide staining in isolated mouse crypts and activation of ferroptosis by RSL3 (1 µM) and erastin (5 µM) (RSL3+Era). Inhibition of ferroptotic cell death by ferrostatin-1 (Fer-1; 5 µM). Bar = 100 µm. Mean ± SEM (number of experiments). # significant difference compared to WT, con, or RSL3+Era, respectively (p < 0.05, unpaired t-test).
Cancers 11 00625 g001aCancers 11 00625 g001b
Cancers 11 00625 g002 550
Figure 2. Reduced ferroptosis in macrophages from mice lacking expression of TMEM16F. (A) Semiquantitative RT-PCR indicating lack of expression of TMEM16F (T16F) in peritoneal macrophages isolated from mice with a tissue specific knockout of TMEM16F (TMEM16Fflox/flox-Cx3cr1-Cre, KO; c.f. Methods). (B) Immunostaining of TMEM16F (green) in WT but not KO macrophages. Nuclei labeling by DAPI (blue). Bar = 20 µm. (C,D) Propidium iodide (PI) staining of WT and KO macrophages and induction by RSL3 + erastin (1/5 µM; RSL3-Era). Inhibition of PI positivity by ferrostatin-1 (Fer-1; 5 µM) and by inhibitors of TMEM16F, niclosamide (niclo; 1 µM), benzbromarone (benz; 5 µM), and CaCCinhAO1 (AO1; 10 µM), respectively. (E) Activation of whole cell currents by RSL3+Era in WT but not KO macrophages, and inhibition of current activation by niclosamide (1 µM). (F) Corresponding current/voltage relationships of currents measured in WT and KO macrophages. (G,H) Measurement of intracellular Ca2+ concentrations before (con, black line) and after incubation with RSL3 and erastin (RSL3+Era, purple), and activation of Ca2+ store release by ATP (100 µM). RSL3+Era significantly increase basal intracellular Ca2+ levels and augment ATP-induced Ca2+ store release. Mean ± SEM (number of experiments). # significant difference when compared with control (p < 0.05, ANOVA). $ significant difference when compared with WT (p < 0.05, ANOVA). § significant inhibition by blockers (p < 0.05, ANOVA).
Figure 2. Reduced ferroptosis in macrophages from mice lacking expression of TMEM16F. (A) Semiquantitative RT-PCR indicating lack of expression of TMEM16F (T16F) in peritoneal macrophages isolated from mice with a tissue specific knockout of TMEM16F (TMEM16Fflox/flox-Cx3cr1-Cre, KO; c.f. Methods). (B) Immunostaining of TMEM16F (green) in WT but not KO macrophages. Nuclei labeling by DAPI (blue). Bar = 20 µm. (C,D) Propidium iodide (PI) staining of WT and KO macrophages and induction by RSL3 + erastin (1/5 µM; RSL3-Era). Inhibition of PI positivity by ferrostatin-1 (Fer-1; 5 µM) and by inhibitors of TMEM16F, niclosamide (niclo; 1 µM), benzbromarone (benz; 5 µM), and CaCCinhAO1 (AO1; 10 µM), respectively. (E) Activation of whole cell currents by RSL3+Era in WT but not KO macrophages, and inhibition of current activation by niclosamide (1 µM). (F) Corresponding current/voltage relationships of currents measured in WT and KO macrophages. (G,H) Measurement of intracellular Ca2+ concentrations before (con, black line) and after incubation with RSL3 and erastin (RSL3+Era, purple), and activation of Ca2+ store release by ATP (100 µM). RSL3+Era significantly increase basal intracellular Ca2+ levels and augment ATP-induced Ca2+ store release. Mean ± SEM (number of experiments). # significant difference when compared with control (p < 0.05, ANOVA). $ significant difference when compared with WT (p < 0.05, ANOVA). § significant inhibition by blockers (p < 0.05, ANOVA).
Cancers 11 00625 g002
Cancers 11 00625 g003 550
Figure 3. Activation of cell death in in Jurkat T-lymphocytes. (A,B) Whole cell patch clamp currents activated by ionomycin (Iono, 1 µM) in Jurkat T lymphocytes, and corresponding current/voltage relationships. (C) Activation of whole cell currents by tert-butyl hydroperoxide (tBHP; 50 μM/6 h) and inhibition of currents by 5Cl. (D,E) Activation of cell death by RSL3 + erastin and inhibition by Figure 1. (Fer-1, 5 µM) or tannic acid (TA, 10 µM). Mean ± SEM (number of experiments). * significant activation by Iono (p < 0.05, paired t-test). # significant difference when compared with scrambled, control, or 5Cl, respectively (p < 0.05, unpaired t-test). $ significant inhibition (p < 0.05, ANOVA).
Figure 3. Activation of cell death in in Jurkat T-lymphocytes. (A,B) Whole cell patch clamp currents activated by ionomycin (Iono, 1 µM) in Jurkat T lymphocytes, and corresponding current/voltage relationships. (C) Activation of whole cell currents by tert-butyl hydroperoxide (tBHP; 50 μM/6 h) and inhibition of currents by 5Cl. (D,E) Activation of cell death by RSL3 + erastin and inhibition by Figure 1. (Fer-1, 5 µM) or tannic acid (TA, 10 µM). Mean ± SEM (number of experiments). * significant activation by Iono (p < 0.05, paired t-test). # significant difference when compared with scrambled, control, or 5Cl, respectively (p < 0.05, unpaired t-test). $ significant inhibition (p < 0.05, ANOVA).
Cancers 11 00625 g003
Cancers 11 00625 g004 550
Figure 4. Phospholipid scrambling by TMEM16F and cooperativity with TMEM16A. (A) Flow cytometry in HEK293 cells expressing TMEM16F, TMEM16A, TMEM16A in the presence of siRNA for TMEM16F, or cells transfected with empty plasmid (mock) or siRNA for TMEM16F. 4-quadrant dot blot graphs showing 7-AAD positivity on y-axis and annexin V positivity on x-axis. Phospholipid scrambling (PS; annexin V positivity) was induced by stimulation of the cells with 1 µM Iono; 10 min). (B) Summary of % annexin V positive cells before and after exposure to ionomycin. Mean ± SEM (number of experiments). # indicates significant difference when compared to control (p < 0.05, unpaired t-test).
Figure 4. Phospholipid scrambling by TMEM16F and cooperativity with TMEM16A. (A) Flow cytometry in HEK293 cells expressing TMEM16F, TMEM16A, TMEM16A in the presence of siRNA for TMEM16F, or cells transfected with empty plasmid (mock) or siRNA for TMEM16F. 4-quadrant dot blot graphs showing 7-AAD positivity on y-axis and annexin V positivity on x-axis. Phospholipid scrambling (PS; annexin V positivity) was induced by stimulation of the cells with 1 µM Iono; 10 min). (B) Summary of % annexin V positive cells before and after exposure to ionomycin. Mean ± SEM (number of experiments). # indicates significant difference when compared to control (p < 0.05, unpaired t-test).
Cancers 11 00625 g004
Cancers 11 00625 g005 550
Figure 5. Cell death induced in cancer cells. (A) Summary of LDH release induced by RSL3 + Era (24 h) in human A549 pulmonary adenocarcinoma, Cal27 head and neck cancer, HT29 colonic carcinoma, and MG-63 osteosarcoma cells, respectively. (B) Summary of LDH release induced in cancer cells by melittin (1 µM/14 h). (C,D) Dot blot indicating cell death induced by melittin in HEK293 cells expressing empty plasmid, TMEM16F, or TMEM16A, respectively. 7-AAD positivity indicating enhanced cell death in cells expressing TMEM16F. (E) Cell death induced by melittin, as detected by LDH release. Mean ± SEM (number of experiments). # Significant induction of LDH release or 7-AAD positivity, respectively (p < 0.05, unpaired t-test). $ Significant inhibition by Fer-1 (p < 0.05, unpaired t-test). § Significant difference compared to mock (p < 0.05, ANOVA).
Figure 5. Cell death induced in cancer cells. (A) Summary of LDH release induced by RSL3 + Era (24 h) in human A549 pulmonary adenocarcinoma, Cal27 head and neck cancer, HT29 colonic carcinoma, and MG-63 osteosarcoma cells, respectively. (B) Summary of LDH release induced in cancer cells by melittin (1 µM/14 h). (C,D) Dot blot indicating cell death induced by melittin in HEK293 cells expressing empty plasmid, TMEM16F, or TMEM16A, respectively. 7-AAD positivity indicating enhanced cell death in cells expressing TMEM16F. (E) Cell death induced by melittin, as detected by LDH release. Mean ± SEM (number of experiments). # Significant induction of LDH release or 7-AAD positivity, respectively (p < 0.05, unpaired t-test). $ Significant inhibition by Fer-1 (p < 0.05, unpaired t-test). § Significant difference compared to mock (p < 0.05, ANOVA).
Cancers 11 00625 g005
Cancers 11 00625 g006 550
Figure 6. Melittin activated cell death of cancer cells. Dot blots indicating cell death (7-AAD positivity) induced by melittin (1 µM/14 h) in A549, Cal27, HT29 and MG-63 cells. Summary of 7-AAD positivity before and after application of melittin. Mean ± SEM (number of experiments). # Significant difference when compared to control (p < 0.05, unpaired t-test).
Figure 6. Melittin activated cell death of cancer cells. Dot blots indicating cell death (7-AAD positivity) induced by melittin (1 µM/14 h) in A549, Cal27, HT29 and MG-63 cells. Summary of 7-AAD positivity before and after application of melittin. Mean ± SEM (number of experiments). # Significant difference when compared to control (p < 0.05, unpaired t-test).
Cancers 11 00625 g006
Cancers 11 00625 g007 550
Figure 7. Activation of VRAC is inhibited by niclosamide. (A,B) Whole cell patch clamp currents activated by hypotonic cell swelling (hypo; 33% hypotonicity) in Jurkat T lymphocytes, and inhibition of VRAC activation by niclosamide (niclo; 1 µM). Summary of single experiments and mean ± SEM indicating significant inhibition of VRAC by niclosamide (p < 0.05, unpaired t-test). * significant activation by (p < 0.05, paired t-test).
Figure 7. Activation of VRAC is inhibited by niclosamide. (A,B) Whole cell patch clamp currents activated by hypotonic cell swelling (hypo; 33% hypotonicity) in Jurkat T lymphocytes, and inhibition of VRAC activation by niclosamide (niclo; 1 µM). Summary of single experiments and mean ± SEM indicating significant inhibition of VRAC by niclosamide (p < 0.05, unpaired t-test). * significant activation by (p < 0.05, paired t-test).
Cancers 11 00625 g007

Share and Cite

MDPI and ACS Style

Ousingsawat, J.; Schreiber, R.; Kunzelmann, K. TMEM16F/Anoctamin 6 in Ferroptotic Cell Death. Cancers 2019, 11, 625. https://doi.org/10.3390/cancers11050625

AMA Style

Ousingsawat J, Schreiber R, Kunzelmann K. TMEM16F/Anoctamin 6 in Ferroptotic Cell Death. Cancers. 2019; 11(5):625. https://doi.org/10.3390/cancers11050625

Chicago/Turabian Style

Ousingsawat, Jiraporn, Rainer Schreiber, and Karl Kunzelmann. 2019. "TMEM16F/Anoctamin 6 in Ferroptotic Cell Death" Cancers 11, no. 5: 625. https://doi.org/10.3390/cancers11050625

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop